Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Depreciation: 2019-2023

Historic Accumulated Depreciation for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2023 value amounting to $29.0 million.

  • Autolus Therapeutics' Accumulated Depreciation rose 21.68% to $29.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $29.0 million, marking a year-over-year increase of 21.68%. This contributed to the annual value of $27.5 million for FY2022, which is 21.24% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Accumulated Depreciation of $29.0 million as of Q3 2023, which was up 0.14% from $29.0 million recorded in Q2 2023.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Depreciation peaked at $29.0 million during Q3 2023, and registered a low of $5.8 million during Q2 2019.
  • Its 3-year average for Accumulated Depreciation is $25.9 million, with a median of $25.5 million in 2022.
  • Data for Autolus Therapeutics' Accumulated Depreciation shows a peak YoY increased of 21.68% (in 2023) over the last 5 years.
  • Autolus Therapeutics' Accumulated Depreciation (Quarterly) stood at $6.8 million in 2019, then reached $9.2 million in 2020, then reached $22.7 million in 2021, then climbed by 21.24% to $27.5 million in 2022, then increased by 21.68% to $29.0 million in 2023.
  • Its Accumulated Depreciation was $29.0 million in Q3 2023, compared to $29.0 million in Q2 2023 and $26.8 million in Q1 2023.